Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825108 | 0.88 | PKM (0.63) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL896463 | 0.87 | PKM (0.54) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL825032 | 0.84 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL253492 | 0.81 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL196221 | 0.81 | PKM (0.56) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL9851568 | 0.80 | PKM (0.63) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL15751296 | 0.79 | PKM (0.61) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL825103 | 0.78 | PKM (0.51) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL5900909 | 0.78 | PKM (0.51) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL21510169 | 0.77 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8143244-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143244-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143244-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2401280-A1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | Bristol-Myers Squibb Company (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099159-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099159-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, EIF2AK2, HCCS | PKM 4825/4885HTT 4589/4885ALDH1A1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.